Score Breakdown
Offering Ability
40
Cash Runway
95
Float Risk—
Warrant Exposure
30
Convertible Debt
40
Dilution Forecast
🌥️
Advisory
Moderate dilution signals present
model est. 34%
💰 Capital Raise
model 55%
• Critical: only 0.1 months cash remaining
📜 Warrant Exercise
model 15%
• Warrant overhang: 5.6% of shares outstanding
📉 Score Deterioration
model 10%
• Score in HIGH risk zone (65/100)
Market Data
Market CapN/A
Shares Outstanding101.92M
FloatN/A
Cash$200.0K
Debt$80.05M
Short InterestN/A
Institutional Holdings
Institutional data not yet available.
Short Interest
No current FINRA short-interest record is available for this ticker.
Recent SEC Activity
xbrl
XBRL WARRANT
2025-12-31
xbrl
XBRL CONVERTIBLE
2025-03-24
Full SEC filing analysis available with free account →
Recent News
No recent news
Factual STLN Dilution Snapshot
Starling Oncology, Inc. (STLN) has a DilutionScore of 65/100, rated High dilution risk. Score date: August 28, 2026.
- Stored outstanding warrants: 5.8M.
- Recent SEC activity tracked for STLN: xbrl on 2025-12-31; xbrl on 2025-03-24.
- Score coverage note: Float Risk is excluded because public-float data is unavailable.
This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.
Related Stocks — HIGH Risk
Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:
📖 Dilution Education
Score Coverage Note
- Float Risk is excluded because public-float data is unavailable.